Article Information
History
- December 5, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kayla E. Hanson, MPH1,
- Kristin Goddard, MPH2,
- Ned Lewis, MPH2,
- Bruce Fireman, MA2,
- Tanya R. Myers, PhD3,
- Nandini Bakshi, MD4,
- Eric Weintraub, MPH3,
- James G. Donahue, DVM, PhD1,
- Jennifer C. Nelson, PhD5,
- Stan Xu, PhD6,
- Jason M. Glanz, PhD7,
- Joshua T.B. Williams, MD8,
- Jonathan D. Alpern, MD9 and
- Nicola P. Klein, MD, PhD2,*
- 1Marshfield Clinic Research Institute, Marshfield, WI
- 2Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA
- 3Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA
- 4The Permanente Medical Group, Oakland, CA
- 5Kaiser Permanente Washington Health Research Institute, Seattle, WA
- 6Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA
- 7Kaiser Permanente Colorado Institute for Health Research, Denver, CO
- 8Ambulatory Care Services, Denver Health & Hospital Authority, Denver, CO
- 9HealthPartners Institute, Minneapolis, MN
- ↵* Corresponding author; email: nicola.klein{at}kp.org
Posted December 05, 2021.
Guillain-Barré Syndrome after COVID-19 Vaccination in the Vaccine Safety Datalink
